Huijie Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huijie Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chunli Yang
Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China
1 shared publication - Kexing Ren
Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China
1 shared publication - Liqun Zou
Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Qian Luo
Department of Haematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China
1 shared publication Qiuluo Liu
Institute of Digestive Surgery, Institute of General Surgery, West China Hospital, Sichuan University, Chengdu, China
1 shared publicationTian Fang
Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 16 June 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (6) , 1-11
KPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma
Background Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive lymphoma in which radioresistance remains a major cause of treatment failure in the relapsed/refractory (R/R) setting. Methods We analysed XPO1 expression in ENKTL and assessed its role in radiosensitization using monoallelic XPO1-knockout models and KPT-330 in vitro and in xenografts. Mechanistic studies focused on the c-Myc–RAD51/CHEK1 axis, and clinical efficacy was evaluated in two R/R patients. Results Immunohistochemistry showed XPO1 overexpression in primary treatment-naïve ENKTL specimens relative to nasal polyp controls, and high XPO1 expression was associated with inferior overall survival. Monoallelic XPO1 knockout impaired homologous recombination (HR) repair, establishing a DNA repair defect exploitable as a radiosensitizing vulnerability. Pharmacologic inhibition of XPO1 with KPT-330 recapitulated these HR defects and synergised with radiotherapy. Mechanistically, KPT-330 disrupts the XPO1–c-Myc–RAD51/CHEK1 axis by blocking c-Myc nuclear export, reducing c-Myc abundance and promoter occupancy at the RAD51 and CHEK1 loci, thereby impairing HR. In two heavily pretreated R/R ENKTL patients, radiotherapy rechallenge plus low-dose KPT-330 achieved one partial response and one complete response with manageable toxicity. Conclusions XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc–RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330–based radiosensitization in R/R ENKTL. The alternative text for this image may have been generated using AI.
- 16 June 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (6) , 1-11
Open AccessKPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma
Background Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive lymphoma in which radioresistance remains a major cause of treatment failure in the relapsed/refractory (R/R) setting. Methods We analysed XPO1 expression in ENKTL and assessed its role in radiosensitization using monoallelic XPO1-knockout models and KPT-330 in vitro and in xenografts. Mechanistic studies focused on the c-Myc–RAD51/CHEK1 axis, and clinical efficacy was evaluated in two R/R patients. Results Immunohistochemistry showed XPO1 overexpression in primary treatment-naïve ENKTL specimens relative to nasal polyp controls, and high XPO1 expression was associated with inferior overall survival. Monoallelic XPO1 knockout impaired homologous recombination (HR) repair, establishing a DNA repair defect exploitable as a radiosensitizing vulnerability. Pharmacologic inhibition of XPO1 with KPT-330 recapitulated these HR defects and synergised with radiotherapy. Mechanistically, KPT-330 disrupts the XPO1–c-Myc–RAD51/CHEK1 axis by blocking c-Myc nuclear export, reducing c-Myc abundance and promoter occupancy at the RAD51 and CHEK1 loci, thereby impairing HR. In two heavily pretreated R/R ENKTL patients, radiotherapy rechallenge plus low-dose KPT-330 achieved one partial response and one complete response with manageable toxicity. Conclusions XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc–RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330–based radiosensitization in R/R ENKTL. The alternative text for this image may have been generated using AI.